久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

加拿大ConjuChem Biotechnologies Inc.
成立于1997年作為紅細胞公司， ConjuChem生物技術有限公司（ “ ConjuChem ”或“公司” ）是一家公開上市交易的加拿大生物技術公司，致力于發(fā)現新的治療方法與最初的重點是糖尿病。
ConjuChem creates novel, next-generation medicines using unique, long-acting therapeutic peptides. Underlying all ConjuChem compounds are bioconjugation platforms called Drug Affinity Construct (DAC?) and Preformed Conjugate-Drug Affinity Construct (PC-DAC?). When applied to a given peptide, DAC? and PC-DAC? can create new drugs with similar therapeutic activities but with significantly longer durations of activity and improved safety profiles.

Founded in 1997 as RedCell Inc., ConjuChem Biotechnologies Inc. ("ConjuChem" or the "Company") is a publicly traded Canadian biotechnology company dedicated to the discovery of novel therapeutics with an initial focus on diabetes.

ConjuChem is currently managing several research programs in-house and has one product in clinical development. We are focused on discovering and developing new drugs based on our novel technology platforms called Drug Affinity Complex (DACTM) and Preformed Conjugate-Drug Affinity Complex (PC-DACTM). When applied to a compound, DACTM or PC-DACTM can create a new drug with similar therapeutic activity but a significantly longer duration of activity in the body. One of the greatest opportunities for the DACTM and PC-DACTM technology from ConjuChem is its ability to harness the therapeutic potential of peptides, which are hindered by a variety of limitations. In particular, peptides have short durations of vivo activity, which not only decrease their efficacy, but can also hold back their commercialization potential.

The DACTM and PC-DACTM technology platforms have broad applicability in several targeted indications. The Company believes there are many attractive potential targets for the constructs being built from these technology platforms. ConjuChem routinely evaluates partnership agreements with other biopharmaceutical firms for research collaborations and licensing agreements while also assessing which programs the Company may consider developing and commercializing on its own.